STOCK TITAN

MARIZYME INC - $MRZM STOCK NEWS

Welcome to our dedicated page for MARIZYME news (Ticker: $MRZM), a resource for investors and traders seeking the latest updates and insights on MARIZYME stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MARIZYME's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MARIZYME's position in the market.

Rhea-AI Summary
Marizyme partners with Qualigen Therapeutics to commercialize FDA-cleared DuraGraft™ for CABG surgeries, with Qualigen providing funding and a share of future profits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
58.33%
Tags
none
-
News
Rhea-AI Summary
Marizyme, Inc. provides a business update on FDA clearance for DuraGraft™ and outlines its business priorities for 2024. The company has secured FDA clearance for DuraGraft™, a vascular conduit solution for CABG surgeries. They plan to penetrate the U.S. market, drive sales in Europe and Asia, reduce expenses, and expand their intellectual property portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.35%
Tags
none
-
Rhea-AI Summary
The Watchlist by The Market Herald releases new interviews with FPX Nickel, Pelangio Exploration, Nicola Mining, and Max Resource
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Marizyme receives FDA clearance for DuraGraft, the first and only medical device for use in CABG surgeries
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
50%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.73%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
MARIZYME INC

OTC:MRZM

MRZM Rankings

MRZM Stock Data

2.57M
13.85M
32.31%
0.01%
Data Processing, Hosting, and Related Services
Information
Link
United States of America
Jupiter

About MRZM

marizyme, inc., a development stage company, focuses on life sciences or biotechnology businesses. it focuses on commercializing therapies that address the urgent needs relating to acute care space. the company was formerly known as gbs enterprises incorporated. marizyme, inc. was incorporated in 2007 and is based in davenport, florida.